

April 01, 2026

**BSE Limited**

Phiroze Jeejeebhoy Towers, Dalal  
Street, Fort, Mumbai – 400001,  
Maharashtra  
Scrip Code – 544709

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400051, Maharashtra  
Symbol – GAUDIUMIVF

Dear Sir/Madam,

**Subject: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of other applicable laws, if any, please find enclosed Press Release titled “Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India”

The above is being made available on the Company’s website i.e. [www.gaudiumivfcentre.com](http://www.gaudiumivfcentre.com).

This is for your information, records and appropriate dissemination.

Thanking you.

**For and on behalf of Gaudium IVF and Women Health Limited**

*(Formerly known as Gaudium IVF and Women Health Private Limited)*

**Naveen Kumar**

Company Secretary and Compliance Officer  
Membership No.: A69788



Encl.: a/a



## Gaudium IVF Introduces AI-Led Infertility Treatment, Marking an Industry First in India

**New Delhi, 1<sup>st</sup> April 2026:** Gaudium IVF, an innovation leader and a pioneering force in India's fertility healthcare sector, has introduced **artificial intelligence (AI)-led infertility treatment**, marking yet another **industry first**—just one month after becoming **India's first publicly listed IVF chain**.

The development involves the integration of advanced AI-driven embryology systems, including **SiD (Sperm Identification Device)** and **ERICA (Embryo Ranking Intelligent Classification Assistant)**, into routine clinical practice. This milestone was formally inaugurated by **Hon'ble Union Minister Shri Nitin Jairam Gadkari, Minister for Road Transport and Highways, Government of India**, who emphasised the role of innovation and technology in shaping the nation's future.

This integration has been undertaken in collaboration with **IVF 2.0**, a UK-headquartered embryology innovation organisation founded by renowned embryologists Dr. Jacques Cohen and Dr. Alejandro Chave. This partnership brings globally advanced embryology intelligence into the Indian clinical ecosystem.

Speaking at the inauguration, **Hon'ble Union Minister Shri Nitin Jairam Gadkari, Minister for Road Transport and Highways, Government of India**, remarked, *"The adoption of advanced technologies such as artificial intelligence reflects India's growing strength in innovation. Initiatives like these will play an important role in shaping the future of technology-led solutions across sectors."*

Commenting on the development, **Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF**, said, *"Fertility care is entering a new era where precision and intelligence will define outcomes. By integrating AI into infertility treatment, Gaudium IVF is not only improving success rates but also bringing greater predictability, transparency, and trust to the patient journey. Our collaboration with IVF 2.0 ensures that global innovations are now accessible to patients within India."*

Speaking about the collaboration, **Giles Palmer, Clinical Scientist and Director of Global Communications, IVF 2.0**, stated, *"Our focus has always been to translate embryology intelligence into measurable clinical outcomes. Partnering with Gaudium IVF allows us to bring our AI-driven solutions into a high-growth market like India and set new benchmarks for how reproductive medicine is practised."*

The newly introduced technologies are designed to enhance critical stages of the IVF process. **SiD or Sperm Identification Device** is an advanced AI system designed to optimise sperm selection during fertility treatments. By analysing various sperm movement parameters, SiD identifies the most viable sperm for fertilisation, which can lead to better-quality blastocyst formation. Complementing this, **ERICA or Embryo Ranking Intelligent Classification Assistant**, an advanced AI-powered tool designed to support embryologists in embryo selection, provides objective, data-driven ranking of embryos. It is done by analysing static images of blastocysts based on key morphological and developmental characteristics.

Together, these non-invasive tools assist embryologists in improving decision-making and reducing variability.

Early clinical observations suggest that the integration of these AI systems can significantly improve fertilisation and blastocyst development rates. By improving precision and consistency, the adoption of AI has the potential to reduce the need for repeat cycles, thereby lowering the emotional, physical, and financial burden on patients while inspiring confidence among clinicians and stakeholders.

#### **About Gaudium IVF and Women Health Limited**

Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility care provider with a PAN India presence and a growing global reach. Recently becoming India's first publicly listed IVF chain, the organisation has consistently pushed the boundaries of reproductive healthcare innovation in the country. With the introduction of AI-led embryology, Gaudium IVF continues to redefine the future of fertility treatment, reinforcing its position as an industry pioneer. Under the leadership of Manika Khanna, the organisation is known for its patient-centric approach, advanced clinical excellence, and continuous focus on innovation in reproductive medicine.